Piclidenoson In The Treatment Of Plaque Psoriasis Overview The study focused on evaluating the effectiveness and safety of piclidenoson (CF101), an orally bioavailable agonist for the A3 adenosine receptor (A3AR), in treating moderate-to-severe plaque psoriasis. The A3AR is known to be overexpressed in the skin and peripheral blood mononuclear cells of individuals
Tag: Piclidenoson
